P-94 Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Abstract

Identification of somatic mutations in ctDNA may detect minimal residual disease (MRD) in patients with curatively treated CRC who may eventually recur. Highly sensitive NGS-based assays are known to have comparable sensitivity to digital PCR approaches, with the added benefit of broader coverage and no requirement for a priori knowledge of tumour-based mutations. The ASpirin for Dukes C and high risk Dukes B COLorecTal cancer trial (ASCOLT, NCT00565708) is a randomised, double-blinded, phase III fully accrued study investigating the benefit and safety of aspirin in the adjuvant setting.